In a pivotal move that could reshape the federal stance on marijuana, a top official at the Department of Health and Human Services (HHS) has recommended that the substance be reclassified as a Schedule III substance under the Controlled Substances Act.
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at